Expert Opinion on Biological Therapy

Article	Citations
Platelet-rich plasma for the treatment of knee osteoarthritis: an expert opinion and proposal for a novel classification and coding system	112
Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia	64
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects	61
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?	58
Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?	57
Mesothelin-targeted CAR-T cell therapy for solid tumors	57
Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics	55
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy	53
Recent developments of RNA-based vaccines in cancer immunotherapy	53
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy	48
Core decompression isolated or combined with bone marrow-derived cell therapies for femoral head osteonecrosis	45
Rationale for IL-15 superagonists in cancer immunotherapy	44
Will plant-made biopharmaceuticals play a role in the fight against COVID-19?	43
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma	41
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology	39
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study	39
Ixekizumab for the treatment of psoriasis: up-to-date	38
Therapeutic monoclonal antibodies for COVID-19 management: an update	37
New frontiers in personalized medicine in psoriasis	37
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study	36
Prospects and challenges for use of CAR T cell therapies in solid tumors	36
Current advances in the algae-made biopharmaceuticals field	36
Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development	35
A tool with many applications: vesicular stomatitis virus in research and medicine	34
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update	34

Immunotherapy for SARS-CoV-2: potential opportunities	31
Progress with stem cell therapies for tendon tissue regeneration	30
Treating psoriasis in the elderly: biologics and small molecules	30
A comprehensive review on sarilumab in COVID-19	30
Nivolumab for the treatment of hepatocellular carcinoma	30
Targeting the complement system in neuromyelitis optica spectrum disorder	30
A randomized blinded retrospective study: the combined use of micro-needling technique, low-level laser therapy and autologous non-activated platelet-rich plasma improves hair re-growth in patients wi	28
The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer	27
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan	27
Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications	26
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics	25
Immune checkpoint inhibition in COVID-19: risks and benefits	23
Anti-CD20 treatment for B-cell malignancies: current status and future directions	23
Anticalin® proteins: from bench to bedside	23
Biologic therapy for advanced breast cancer: recent advances and future directions	23
A health economic guide to market access of biosimilars	23
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma	23
Enzyme therapy: a forerunner in catalyzing a healthy society?	23
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?	22
Hemophilia A gene therapy: current and next-generation approaches	21
What makes a good antibody–drug conjugate?	21
Margetuximab for the treatment of HER2-positive metastatic breast cancer	21
Isatuximab for the treatment of relapsed/refractory multiple myeloma	21
Abicipar pegol for neovascular age-related macular degeneration	21
AIRMESS – Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic	20
Regenerative medicine for spinal cord injury: focus on stem cells and biomaterials	20
Regenerative application of stromal vascular fraction cells enhanced fat graft maintenance: clinical assessment in face rejuvenation	20
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis	20
Small extracellular vesicles (sEVs): discovery, functions, applications, detection methods and various engineered forms	20
Atezolizumab in the treatment of metastatic triple-negative breast cancer	20
Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy	19
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical	19
Current and emerging biologics for the treatment of juvenile idiopathic arthritis	19
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19	19
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy	19
Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery	18
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions	18
Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders	18
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy	18
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management	18
Rotavirus vaccines: progress and new developments	18
Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy	18
Enfortumab vedotin – next game-changer in urothelial cancer	17
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer	17
Therapeutic potential of biologics in prurigo nodularis	17
Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus	17
Biologics in severe asthma: the overlap endotype - opportunities and challenges	16
Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces	16
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	16
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis	15

Prostate cancer immunotherapy	15
Cell therapy for type 1 diabetes	15
Ranibizumab for the treatment of diabetic retinopathy	15
B7-H3 targeted antibody-based immunotherapy of malignant diseases	15
Antibody-drug conjugates for multiple myeloma	15
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy	15
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era	15
Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa	15
RNA therapeutics for retinal diseases	14
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders	14
The evolution of bispecific antibodies	14
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond	14
HIV-1 cure strategies: why CRISPR?	14
Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity	14
An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation	13
Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update	13
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy	13
Antibody-based therapies for idiopathic pulmonary fibrosis	13
CGRP pathway monoclonal antibodies for cluster headache	13
Toripalimab for the treatment of melanoma	13
Rituximab treatment of ANCA-associated vasculitis	13
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?	13
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD	13
Injectable and adhesive hydrogels for dealing with wounds	13
Survivin as a biological biomarker for diagnosis and therapy	13
Self-administration of omalizumab: why not? A literature review and expert opinion	12
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice	12
Denosumab for cancer-related bone loss	12
Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy	12
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma	12
Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors	12
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults	12
The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database	12
Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities	12
Ranibizumab for myopic choroidal neovascularization	12
Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?	12
Targeting glyco-immune checkpoints for cancer therapy	12
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy	12
Pembrolizumab for the treatment of esophageal cancer	12
Liver-directed gene-based therapies for inborn errors of metabolism	11
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer	11
Luspatercept for β-thalassemia: beyond red blood cell transfusions	11
Pembrolizumab for the treatment of Hodgkin Lymphoma	11
Ustekinumab for treating ulcerative colitis: an expert opinion	11
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?	11
Guselkumab for the treatment of palmoplantar pustulosis	10
Bispecific antibodies for the treatment of breast cancer	10
IL-23 inhibition for the treatment of psoriatic arthritis	10
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phas	10
A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis	10
Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system	10
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy	10
Current and emerging biologic therapies for triple negative breast cancer	10
Up-to-date role of biologics in the management of respiratory syncytial virus	10
Antibody-drug conjugates for the treatment of ovarian cancer	10
Cord blood transplantation for acute leukemia	10
Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience	10
Antibody–drug conjugates to treat gastric cancer	10
Biologic therapies for the treatment of hidradenitis suppurativa	10
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma	10
Eculizumab for the treatment of myasthenia gravis	10
Biologics in food allergy: up-to-date	10
AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins	9
CRISPR/Cas9 gene editing therapies for cystic fibrosis	9
Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review	9
Anthrax prevention through vaccine and post-exposure therapy	9
Gene Therapy for High Grade Glioma: The Clinical Experience	9
Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy	9
Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective	9
Evaluation of canine bone marrow-derived mesenchymal stem cells for experimental full-thickness cutaneous wounds in a diabetic rat model	9
Immunotherapy for castration-resistant prostate cancer: has its time arrived?	9
Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars	9
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives	9
A review of imlifidase in solid organ transplantation	9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	9
Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13	9
Belimumab: a step forward in the treatment of systemic lupus erythematosus	9
Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus	9
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	9
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations	9

Approval of biosimilars: a review of unsuccessful regulatory filings	8
Emerging treatment landscape of non-muscle invasive bladder cancer	8
Platelet-rich plasma therapy ensures pain reduction in the management of lateral epicondylitis – a PRISMA-compliant network meta-analysis of randomized controlled trials	8
Cell therapy for cytomegalovirus infection	8
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma	8
Bio-nano scale modifications of melittin for improving therapeutic efficacy	8
Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview	8
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience	8
Biosimilars in psoriasis: what should your positioning be?	8
Biological agents targeting interleukin-13 for atopic dermatitis	8
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk	8
The emerging role of dupilumab in dermatological indications	8
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	8
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)	8
Biosimilars: A futuristic fast-to-market advice to developers	8
Role of extracellular vesicles in severe pneumonia and sepsis	8
Brief overview of antibody–drug conjugate therapy for acute leukemia	8
Pediatric use of omalizumab for allergic asthma	8
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study	8
Tocilizumab for the treatment of COVID-19	8
Expanding use of CD33-directed immunotherapy	8
Oncolytic virus therapy for malignant gliomas: entering the new era	8
The Role of Anti-IL-1 Treatment in MIS-C Patients	8
Immune checkpoint inhibitors for the treatment of melanoma	8
Ligelizumab for the treatment of chronic spontaneous urticaria	8
Nivolumab for the treatment of esophageal cancer	8
Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method	8
Alternative therapeutic strategy for existing aortic aneurysms using mesenchymal stem cell–derived exosomes	8
Host-directed therapies: a potential solution to combat COVID-19	8
Brodalumab in the treatment of chronic plaque psoriasis	8
Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer	7
Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides	7
Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective	7
Current developments in gene therapy for epidermolysis bullosa	7
Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs	7
Anti-IL 23 biologics for the treatment of plaque psoriasis	7
Up-to-date role of the dehydrated human amnion/chorion membrane (AMNIOFIX) for wound healing	7
Cell-based therapy in soft tissue sports injuries of the knee: a systematic review	7
Current status of probiotics for prevention and management of gastrointestinal cancers	7
The manufacturing considerations of bispecific antibodies	7
Classification and coding systems for platelet-rich plasma (PRP): a peek into the history	7
Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques	7
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	7
Emerging therapies for human hearing loss	7
Anti-CD6 mAbs for the treatment of psoriasis	7
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence	7
Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing	7
Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-19	7
Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy	6
A state-of-art review on collagenase Clostridium Histolyticum and Peyronie’s disease: drug profile, clinical evidence and safety outcomes	6
The global landscape on interchangeability of biosimilars	6
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis	6
Precursors of thymic peptides as stress sensors	6
Current and Future Options of Haemophilia A Treatments	6
Advanced clinical imaging for the evaluation of stem cell based therapies	6
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	6
Paradoxical reactions to biologicals for psoriasis	6
Eptinezumab for the treatment of migraine	6
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer	6
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	6
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	6
Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia	6
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin	6
Rilonacept for the treatment of recurrent pericarditis	6
Pathogenesis-oriented therapy of psoriasis using biologics	6
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors	6
CAR-NK cells: a promising cellular immunotherapy in lymphoma	6
Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men	6
Regenerative replacement of neural cells for treatment of spinal cord injury	6
Current status of developing tissue engineering vascular technologies	5
Potential applications of mesenchymal stem cells and their derived exosomes in regenerative medicine	5
Bioengineering lungs — current status and future prospects	5
Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective	5
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	5
The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review	5
Anti-TNF biosimilars in rheumatology: the end of an era?	5
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	5
The effect of drugs used in rheumatology for treating SARS-CoV2 infection	5
Biological medication in atopic dermatitis	5
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	5
Unsolved problems and new medical approaches to otitis media	5
Current and emerging biologics for the treatment of pediatric atopic dermatitis	5
Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors	5
The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia	5
Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α anta	5
Bispecific antibodies for immune cell retargeting against cancer	5
Biomedical applications of muscle-derived stem cells: from bench to bedside	5
Flow cytometry and receptor occupancy in immune-oncology	5
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe	5
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission	5
Bispecific CAR T-cells for B-cell Malignancies	5
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	5
Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?	5
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	5
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	5